Skip to main content
. 2011 Apr 27;102(6):1137–1143. doi: 10.1111/j.1349-7006.2011.01936.x

Figure 4.

Figure 4

 Relationships between Insig2 mRNA expression levels in microdissected cells and clinicopathological factors. (a) The levels of Insig2 mRNA expression are significantly higher in patients with lymph node metastasis (n = 18) than in those without lymph node metastasis (n = 11) (P = 0.003). (b) According to the UICC classification, the levels of Insig2 mRNA expression are significantly higher in stage IIB–IV cases (n = 20) than in stage I–IIA cases (n = 9) (P = 0.0321). (c) The levels of Insig2 mRNA expression are significantly higher in patients with distant metastasis (lung or liver) and peritoneal dissemination (n = 9) than in patients with local recurrence (n = 3) (P = 0.0124). (d) Relative levels of Insig2 mRNA expression in microdissected normal pancreatic ductal cells from 15 cases with IDC and 17 cases with pancreatic cystic disease, intraductal papillary mucinous neoplasm (IPMN), or other cancers. There is a tendency toward higher levels of Insig2 mRNA expression in normal ductal cells of patients with IDC than in those of patients with pancreatic cystic disease, IPMN, or other cancers (P = 0.062). (e) Survival curves based on Insig2 mRNA expression in microdissected tissues.